Increased lipase inhibition in uremia: Identification of pre-β-HDL as a major inhibitor in normal and uremic plasma  by Cheung, Alfred K. et al.
Kidney International, Vol. 49 (1996), pp. 1360—1371
Increased lipase inhibition in uremia: Identification of
pre--HDL as a major inhibitor in normal and uremic plasma
ALFRED K. CHEUNG, CHARLES J. PARKER, KuIsHu REN, and PER-HENRIK IVERIUS
Medical Service, Veterans Affairs Medical Center, and Department of Internal Medicine, University of Utah School of Medicine,
Salt Lake City, Utah, USA
Increased lipase inhibition in uremia: IdentifIcation of pre--HDL as a
major inhibitor in normal and uremic plasma. The hypertriglyceridemia
commonly observed in uremia has been attributed to an abnormally high
inhibitor activity in plasma for lipoprotein lipase (LPL) and hepatic lipase(HL), both of which have a key role in lipoprotein metabolism. The
purpose of this investigation was to establish a relationship between
plasma lipase inhibitor activity and hypertriglyceridemia, identify the main
plasma lipase inhibitor, and determine the basis for the greater inhibitor
activity in uremia. In a mixed population of normal (N = 8) and uremic
subjects (N = 12), log-transformed plasma triglycerides correlated with
both inhibitor activity and uremic status. However, inhibitor activity was
the only retained predictor variable for triglycerides in a multiple linear
regression model (r = 0.91; P < 0.0001). An inhibitor isolated from
normal plasma was identified as a particle containing apolipoprotein A-I
(apo A-I) and 3% phospholipid. This particle, which has pre-p electro-
phoretic mobility and a Stokes' radius of 54 A, therefore corresponds to a
form of the previously described pre-J3-HDL (free apo A-I) in the
non-lipoprotein fraction of plasma. Comparison of normal and uremic
plasma indicated that the greater lipase inhibitor activity in the latter
could be attributed to an increased concentration of apo A-I in the
non-lipoprotein fraction of plasma (pre-/3-HDL), as well as to increased
inhibition by the uremic lipoproteins. The increased plasma lipase inhib-
itor activity may be important in the pathogenesis of hypertriglyceridemia
in chronic renal failure.
Atherosclerosis and cardiovascular death are common among
hemodialysis patients. Although the cause is probably multifacto-
rial, the dyslipidemia associated with chronic renal insufficiency
appears to be a major risk factor [1]. The principal features of the
deranged lipid metabolism in uremic subjects include an increase
in the VLDL and IDL fractions leading to moderate hypertriglyc-
eridemia, an unchanged or slightly increased LDL fraction en-
riched with triglycerides, and a decrease in the HDL2 subfraction
of HDL resulting in decreased concentration of HDL-cholesterol
[2—4]. The etiology of elevated VLDL and IDL in uremia has not
been fully elucidated, but available data suggest a defect in the
catabolism of the triglyceride-rich lipoproteins [3, 5]. This is likely
to be related to the decreased activity of lipoprotein lipase (LPL)
and hepatic lipase (HL), both of which have a key role in
lipoprotein metabolism [6—8].
LPL and HL are homologous enzymes which are anchored to
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heparan sulfate on the surface of endothelial cells. LPL is found
in the capillaries of most tissues where it hydrolyzes triglycerides
transported by chylomicrons and VLDL, thereby making free
fatty acids available for uptake by the tissues for use as metabolic
fuel or for storage [9]. HL is confined mainly to the liver
endothelium where it participates in the processing of VLDL
remnants to LDL and in the conversion of HDL2 to HDL3 [10].
After an intravenous injection of heparin which temporarily
releases both enzymes into the circulation, their activity can be
measured in the postheparin plasma.
One explanation offered for the impaired postheparin lipase
activities in renal failure, particularly for LPL, has been a de-
creased lipase activity as a result of secondary hyperparathyroid-
ism. This decrease in LPL activity is more likely to be caused by
parathyroid hormone-induced insulin resistance [5] rather than a
direct effect of parathyroid hormone on LPL [11]. Alternatively,
increased lipase inhibitor activity demonstrated in uremic plasma
has been implicated [12—14]. Murase et al [12] found that most
lipase inhibitor activity was in the non-lipoprotein fraction of
plasma and could be precipitated with TCA. Although these
findings would indicate that the inhibitor is a protein, it has never
been isolated and characterized.
The present work was undertaken to isolate and characterize
the major lipase inhibitor in plasma and explore the differences in
inhibitor activity between plasma from normal and uremic sub-
jects. The main plasma lipase inhibitor was found to be an apo
A-I-containing particle of pre-3-electrophoretic mobility and min-
imal lipid content. This particle, or similar apo A-I-containing
particles residing in the lipoprotein-free fraction of plasma,
appeared to be increased in uremic plasma and, along with
qualitative differences in the lipoproteins, account for the greater
lipase inhibitor activity in uremia.
Methods
Experimental subjects
Normal healthy subjects were recruited by local advertizing.
Clinically stable patients on chronic hemodialysis three times a
week for at least three months using cellulose acetate membrane
dialyzers (CA series, Baxter Healthcare Corporation, McGaw
Park, IL, USA), were chosen at random without prior knowledge
of their plasma triglyceride concentrations. All subjects were on
their usual diet and none was taking a lipid lowering agent.
Fasting morning blood samples were collected in EDTA-tubes
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(Becton Dickinson, Rutherford, NJ, USA) and the plasma ob-
tained by centrifugation was kept at 4°C until used later the same
day for fractionation or for assay of lipase inhibitor activity or
triglyceride concentration. The uremic subjects were sampled
immediately before dialysis and anticoagulation with heparin. To
obtain postheparin plasma, a normal subject was sampled 10
minutes after the intravenous injection of heparin (60 units/kg).
The blood was chilled on ice until centrifuged and the plasma was
flash frozen in aliquots and stored at —70°C. Uremic plasma
ultrafiltrate was obtained from a patient during extracorporeal
circulation using a high flux polysulfone membrane hollow fiber
dialyzer (F80, Fresenius, Concord, CA, USA). The ultrafiltrate
(1000 ml) was collected from the dialysate outflow port over one
hour prior to dialysis. The patient was a male who had been on
chronic hemodialysis for three years. Informed consent was
obtained as approved by the Institutional Review Board at the
University of Utah.
Other materials
Polyethylene glycol (PEG; molecular wt 20,000) was obtained
from Sigma Chemical Co. (St. Louis, MO, USA). Goat antiserum
to human apo A-I was purchased from Calbiochem Corp. (La
Jolla, CA, USA). The IgG fraction was isolated from the anti-
serum by caprylic acid precipitation of extraneous proteins and
dialyzed against PBS [15]. Apo A-I was purified from normal
plasma by a modification of a published procedure [16]. Briefly,
HDL isolated by ultracentrifugation was lyophilized, delipidated
three times in chloroform-methanol (2:1, vol/vol) and twice in
diethyl ether, before fractionation by gel chromatography on a
column (1.6 X 100 cm) of Sephacryl S-200 (Pharmacia Biotech,
Piscataway, NJ, USA) in 6 M urea—0.2 M Tris-HC1 buffer (pH 8.2).
The fractions containing apo A-I were pooled, dialyzed against 10
mM ammonium bicarbonate, lyophilized, redissolved in 4 M gua-
nidine hydrochloride—SO mrvi ammonium bicarbonate (pH 7.8)
and finally dialyzed against 50 mrvi ammonium bicarbonate. The
protein concentration was adjusted to 5 mg/mI after measuring
the absorbance at 280 nm (A2800'°= 1.22) and the solution stored
frozen at —70°C. Human apoC-Ill was obtained from Organon
Teknika (Rockville, MD, USA).
Lipase inhibitor assay
The assay for lipase inhibitor activity was a scaled-down mod-
ification of a lipase activity assay described previously [17, 18]. A
radioactive triglyceride-phospholipid emulsion was prepared by
sonication as described and an aliquot (0.15 ml) was mixed with an
appropriately diluted inhibitor sample or buffer blank (0.075 ml).
Finally, human post-heparin plasma mixed with an equal volume
of 0.2 mg/ml of heparin in KRP was added (0.025 ml) to the assay
as the source of lipase activity and activator (apo C-Il). The
complete assay mixture was incubated at 37°C for 60 minutes after
which the reaction was terminated by taking a 0.2 ml aliquot for
extraction of liberated labeled free fatty acid and liquid scintilla-
tion counting. Lipase inhibitor activity was expressed as the
percent decrease in apparent enzyme activity compared to a
buffer blank. The assay had a linear dose-response curve between
10 and 70% inhibition. A lipase inhibitor unit (InhU) was defined
as the amount of inhibitor that decreased the enzyme activity in 1
ml of complete assay mixture by 50%. The sensitivity of the assay
was essentially doubled by using post-heparin plasma rather than
purified bovine LPL as the enzyme source. Using a mouse
monoclonal antibody (5D2) that inhibits LPL but not HL [19], the
lipase inhibitors in human plasma were found to affect LPL and
HL to a similar degree (data not shown).
Column chromatography
All chromatographies were performed at room temperature in
an automated mode using an FPLC system from Pharmacia LKB
Biotechnology, Inc. (Uppsala, Sweden). Standards (Pharmacia)
used for determination of molecular size by analytical gel chro-
matography included Blue Dextran 2000, thyroglobulin (669 kDa;
Stokes' radius 85 A), aldolase (158 kDa; 48.1 A), albumin (67
kDa; 35.5 A), ovalbumin (43 kDa; 30.5 A), and ribonuclease A
(13.7 kDa; 16.4 A).
Ultracentrifugation
Plasma lipoproteins (density < 1.21) were separated from the
non-lipoprotein fraction by ultracentrifugation in a 70.1 Ti rotor
(Beckman Instruments, Inc.) at 60,000 rpm and 15°C for 22 hours,
after adjusting the plasma to d 1.21 with KBr (0.3252 g to 1 ml).
Alternatively, the separation at d 1.21 was carried out in a 50.3 Ti
rotor at 48,000 rpm and 15°C for 36 hours. For isolation of HDL
(density 1.063 to 1.21), the lipoprotein fraction was dialyzed
against density 1.063 buffer, and spun in the 50.3 Ti rotor at 48,000
rpm for 24 hours. Top or bottom fractions were harvested by tube
slicing.
Single vertical spin ultracentrifugation of a plasma inhibitor
fraction was a modification of a published method (procedure 12)
by Chung et a! [20]. The density gradient was fractionated by
displacement from the bottom of the tube using a Beckman
Fraction Recovery System (Beckman Instruments, Inc.) and a
Harvard model 975 pump (Harvard Apparatus, Southnatick, MA,
USA).
Elect ropho resis
Agarose gel electrophoresis was performed in 1% gels and 0.05
M sodium barbital buffer (pH 8.6) at 90 V for 35 minutes using a
pre-cast gel (Lipoprotein System; Ciba Corning Diagnostics
Corp., Palo Alto, CA, USA). Dried gels were stained for lipid with
Fat Red 7B or for protein with Fast Stain (Zoion Research,
Allston, MA, USA).
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was per-
formed under non-reducing conditions using a 12% gel [21]. The
gels were stained either by Coomassie Brilliant blue or electro-
blotted onto Immobilon PVDF (Millipore, Bedford, MA, USA).
The blot was immunostained with monospecific goat anti-human
apo A-I IgG (Calbiochem, San Diego, CA, USA) followed by
alkaline phosphatase-conjugated protein A (Sigma).
Other methods
Triglyceride concentration in plasma samples was determined
by a CX7 autoanalyzer and reagents for an enzymatic colorimetric
assay from Beckman (Brea, CA, USA). In other samples, triglyc-
eride and total cholesterol were measured using commercial kits
from Sigma. Free cholesterol was measured by a kit from Boehr-
inger Mannheim (Indianapolis, IN, USA). Lipid phosphorus was
determined by the method of Bartlett [22]. Protein concentration
was analyzed by measuring the absorbance at 280 nm or by a
colorimetric method with bicinchoninic acid [23] using commer-
cial reagents (BCA Protein Assay Reagent; Pierce, Rockford, IL,
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Fig. 1. Linear regression of log-transfoimed plasma triglyceride concentra-
tion on lipase inhibitor activity. Plasma was obtained from fasting uremic
(•) and normal (0) subjects. The triglycerides in uremic subjects (163
88 mgldl; range 66 to 321; N = 12) were significantly higher than those in
normal subjects (87 25 mgldl; range 44 to 122; N = 8) by the
Mann-Whitney U-test (P = 0.037). Similarly, the inhibitor activity in
uremic subjects (6.5 2.3 InhU/ml; range 3.0 to 10.5; N 12) was
significantly higher (P = 0.008) than that in normal subjects (3.8 1.3
InhU/ml; range 2.8 to 6.3; N = 8). The pooled data from all subjects (N =
20) were analyzed by multiple linear regression with log-transformed
triglyceride concentration as the dependent variable. The predictor vari-
ables, inhibitor activity (InhU/mI) and uremic status (normal = 0; uremic
= 1), were tested by the stepwise procedure using default selection and
exclusion criteria. The linear regression model retained inhibitor activity
only as a significant independent predictor of triglyceride concentration(r = 0.91; P < 0.0001).
Sample concentration in assay, (%, vol/vol)
Fig. 2. Dose-response curves for lipase inhibition by uremic plasma ultrafil-
trate (V) in comparison with uremic (•) and nonnal (0) plasma. The
ultrafiltrate which had a protein concentration of 5 mg/mI (absorbance at
280 nm) was coltected from a dialysis patient using a polysulfone
membrane (see Methods). Uremic plasma was obtained from the same
patient predialysis. Various dilutions of ultrafiltrate and plasma were then
assayed for lipase inhibitor activity. While the uremic plasma showed
higher lipase inhibition than normal plasma, no significant inhibitor
activity was detected in the ultrafiltrate.
uremic plasma (163 88 mg/dl) was significantly higher (P =
0.037) than that of normal plasma (87 25 mg/dl). Similarly, the
inhibitor activities of uremic (6.5 2.3 InhU/mI) and normal
plasma (3.8 1.3 InhU/ml) were also significantly different (P =
0.008).
The variability of plasma triglyceride concentration (log-nor-
malized) as a function of inhibitor activity and coded uremic
status (normal = 0; uremic = 1),was analyzed by linear regression
(Fig. 1). In the pooled data from normal and uremic subjects (N =
20), the triglycerides correlated to both inhibitor activity (r = 0.91;
P < 0.000 1) and uremic status (r = 0.50; P = 0.024). In a multiple
linear regression model, however, only inhibitor activity was
retained as a significant predictor variable. These results confirm
that plasma contains lipase inhibitor activity that is higher in
uremic than in normal subjects, and corroborate the notion that
this inhibitor activity is a major determinant of hypertriglyceride-
mia in uremia.
Isolation of lipase inhibitor from normal plasma
To identify the plasma lipase inhibitor activity, its isolation was
attempted. Because preliminary experiments indicated that it was
present in normal as well as uremic plasma (Figs. 1 and 2) but not
in uremic ultrafiltrate (Fig. 2), and the availability of uremic
plasma is limited, normal plasma was chosen as the starting
material.
Precipitation of plasma with ammonium sulfate at 50% satura-
tion between pH 6.5 and 4.5 [241 recovered approximately 90% of
the plasma inhibitor activity while the specific inhibitor activity
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USA). Apo A-I concentration was determined using an immuno-
turbidimetric assay (Sigma). For compositional analysis of the
isolated inhibitor, protein was determined by the BCA assay.
Phospholipid was calculated as lipid phosphorus X 25, cholesteryl
ester as cholesterol oleate, and triglyceride as triolein.
Statistical analysis
All analyses were carried out using the SPSS/PC+ software
(SPSS Inc., Chicago, IL, USA). The Mann-Whitney U-test (two-
tailed probability corrected for ties) was used for comparison of
two independent samples. Plasma triglyceride concentrations
were normalized by log-transformation before parametric testing.
Data are presented as means SD.
Results
Relationship between plasma triglyceride concentration and lipase
inhibitor activity in uremic and normal subjects
To confirm that plasma contains lipase inhibitor activity and to
demonstrate its putative role in lipoprotein metabolism, fasting
plasma from normal (N = 8) and uremic subjects (N = 12) was
analyzed (Fig. 1). The triglyceride concentration (mean SD) in
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Table 1. Isolation of lipase inhibitor from normal plasma
Fraction
Volume
ml
Proteinu
mg
Inhibitor
activity
InhU
-
Specific inhibitor
activity
Inh U/mg
Purification
factor
fold
Yield
%
Plasma 90 5440 1123 0.2 1 100
Ammonium sulfate 25 635 1022 1.6 8 91
precipitation"
Q-Sepharose 59 140 375 2.7 13 33
anion exchange
Heparin-Sepharose 76 100 419 4.2 20 37
adsorption
Q-Sepharose and 3 82 328 4.0 19 29
PEG concentration
Superdex-200 19 11.4 183 16.0 76 16
chromatography
PEG concentration 5 8.2 108 13.2 63 9.6
Single vertical spin 1.2 1,4 29.7 21.2 101 2.6 (3.9)C
ultracentrifugation
a Determined by measuring absorbance at 280 nm
"Plasma (90 ml) was diluted 2-fold with water, chilled, and precipitated with 52.4 g of ammonium sulfate after adjusting to pH 6.5 with 1 M MCi. The
supernatant was brought to pH 4.5 and the new precipitate was dissolved in buffer (see legend to Fig. 3) and dialyzed.
C The yield within the brackets was calculated assuming that the entire preceding fraction (8.2 mg) rather than part of that fraction (5.3 mg) was used.
0 Fig. 3. Anion exchange chromatography of lipaseinhibitor from normal plasma on Q-Sepharose.
The inhibitor fraction (635 mg) obtained by
o 4 ammonium sulfate precipitation of plasma(Table 1) was dialyzed against 0.1 M NaCl-1 mM
EDTA-0.05 M Tris-HCI buffer (pH 8.0), diluted
0.3 to 25 ml and applied to a Q-Sepharose column(2.6 X 18.5 cm) equilibrated with the same
buffer. The column was operated at a flow rate
0.2 Ce of 2.5 mI/mm while 5 ml fractions wereZ collected. After washing with 200 ml of buffer,
the column was eluted with a linear gradient
0.1 (600 ml) of 0.1 to 0.5 M NaCl in 1 mM EDTA-
0.05 M Tris-HCI buffer (pH 8.0). The fractions
were monitored by measuring absorbance at
280 nm and inhibitor activity. The thirteen
fractions between the vertical arrows were
pooled for further purification. Symbols are:
(0) absorbance; (•) inhibitor activity; (———)
NaC1 concentration.
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increased eightfold (Table 1). The dissolved precipitate was
fractionated by anion exchange chromatography on a Q-Sepha-
rose column (Fig. 3). A major part of the inhibitor activity
appeared as one peak which emerged early in the salt gradient
while most of the protein was eluted later. The fractions of the
highest specific activity were pooled, dialyzed free of salt and
passed over a heparin-agarose column which removed approxi-
mately 30% of the total protein while all inhibitor activity
emerged with the breakthrough (Fig. 4 legend). Therefore, the
inhibitor lacks affinity for heparin. The sample was then concen-
trated and fractionated by gel chromatography on Superdex-200
(Fig. 4). Most of the inhibitor activity emerged in a single peak
concordant with a protein peak. The elution position in the
chromatogram corresponded to a Stokes' radius of 54 A or a
molecular weight of 230 kDa for a globular protein (Fig. 5). The
inhibitor fraction obtained by gel chromatography was concen-
trated and finally resolved into two peaks by density gradient
ultracentrifugation in a single vertical spin (Fig. 6). Most of the
inhibitor activity was found in the protein peak of high density.
The fractions in this peak (designated hereinafter as the purified
inhibitor) were pooled and analyzed for protein purity and lipid
composition. The purification procedure is summarized in Table
1.
Preliminary SDS-PAGE of the inhibitor fraction obtained after
gel chromatography demonstrated one major protein with an
apparent molecular weight of 28 kDa. Because apo A-I, the major
apolipoprotein of HDL has the same size 25], further testing was
performed to confirm its identity. Figure 7 shows an SDS-PAGE
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Fig. 4. Gel chromatography of partially purified lipase inhibitor from normal
plasma. The pooled inhibitor fraction obtained from the Q-sepharose
column (Fig. 3) was dialyzed against 1 mai EDTA-0.05 M Tris-HCI buffer
(pH 8.0), and passed through a heparin-agarose column (1.6 X 11 cm) to
remove heparin-binding proteins (data not shown). The effluent was
concentrated by desorption from a minicolumn (10 ml) of Q-Sepharose
with 15 nil of 0.5 M NaCI-1 mai EDTA-0.05 M Tris-HCI buffer (pH 8.0)
followed by further concentration in a dialysis bag submerged in dry PEG.
An aliquot of the concentrated sample (54 mg) was then fractionated on
a Superdex-200 16/60 HiLoad column in 0.1 M NaCI-1 mat EDTA-0.05 at
Tris-HCI buffer (pH 8.0) at a flow rate of 0.7 mI/rn in. The fractions (1 ml)
were analyzed for absorbance at 280 nm (0) and inhibitor activity (•).
The fractions with high specific inhibitor activity between the vertical
arrows were pooled. This chromatography step was repeated with the
other aliquot (27 mg) and the pooled fractions were combined (data not
shown). The elution volume of the peak inhibitor activity (62 ml)
corresponded to a Stokes' radius of 54 A or a globular protein of 230 kDa.
0.6 0.8 1.0 1.2 1.4 1.6 1.8
(IflKav) 1/2
Fig. 5. Molecular size of plasma lipase inhibitor determined by gel chroma-
tography. The elution position of the inhibitor in the preparative gel
chromatography on Superdex-200 (Fig. 4) was used to calculate apparent
molecular weight (A) and Stokes' radius (B), after calibrating the column
with molecular standards (see Methods). was calculated as described
by Laurent and Killander [66] after determination of the void volume (V0)
and total volume (Vi) using blue dextran and tritiated water, respectively.
The standard curves were obtained by linear regression.
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and an immunoblot of the purified inhibitor obtained after the
single vertical spin. The sample contained only one predominant
protein with the same electrophoretic mobility as purified apo
A-I. An immunoblot showed that the purified inhibitor contained
apo A-I as the only major protein. Moreover, the inhibitor activity
was completely neutralized by pre-incubation with anti-apo A-I
IgG (data not shown). Further chemical analysis showed that the
inhibitor contained 95.8% (wt/wt) protein, 3.4% phospholipid and
0.8% of free plus esterified cholesterol, while there was no
measurable triglyceride.
The purified inhibitor was also analyzed by non-denaturing
electrophoresis in 1% agarose followed by protein and lipid
staining (Fig. 8). There was only one major band which had
pre-/3-mobility and stained for protein but not for lipid.
The isolation procedure, described above and summarized in
Table 1, resulted in a 100-fold purification of a plasma inhibitor
with a 4% yield. This inhibitor had a homogeneous electro-
phoretic mobility and size (230,000 Da). Assuming that the
inhibitor contained apo A-I (28,331 Da) as the only protein and
that the average molecular weight of its phospholipid was 774 Da
(lipid phosphorus x 25), the apo Al/phosphorus molar ratio was
calculated to 1:1.26. This suggested that the basic structure of the
inhibitor was an equimolar complex of apo A-I and phospholipid
(29,105 Da). The molecular size (230,000 Da) determined by gel
chromatography is therefore in excellent agreement with the
calculated size for an apo A-I/phospholipid octamer (233,840 Da).
Comparison of dose-response curves for different lipase inhibitors
To determine whether the purified inhibitor was sufficiently
potent to have a physiological role, its inhibition of post-heparin
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Fig. 6. Single vertical spin density gradient ultracentnfugation. An aliquot
(5.3 mg) of the inhibitor fraction obtained by gel chromatography (Fig. 4)
was adjusted to density 1.34 by the addition of solid KBr, transferred to a
dialysis bag, and concentrated by submersion in dry PEG. The sample (1.0
ml) was transferred to the bottom of a 5 ml ultracentrifuge tube after
which solutions of d 1.21 (2 ml) and d 1.06 (2.4 ml) were layered
sequentially on top of the sample. The separation was carried out in a
VTi8O rotor at 80,000 rpm and 7°C for 90 minutes. The fractions (0.193
ml), which were collected by displacing the gradient from the bottom of
the tube, were analyzed for absorbance at 280 nm, total cholesterol, and
inhibitor activity. Fractions between the two arrows on the left and the two
arrows on the right were pooled separately. The former pool with the
lower density and specific inhibitor activity was identified as HDL with apo
A-I (data not shown). The latter pool with the higher density and specific
inhibitor activity was designated the lipase inhibitor. Symbols are: (LII)
cholesterol; (0) absorbance; (•) inhibitor activity.
plasma lipases was tested at different concentrations. For com-
parison, dose-response curves were also generated for purified
A-I containing less than 3% (mol/mol) of phospholipid, apo C-Ill,
and HDL with apo A-I (Fig. 9). The latter was the top fraction
obtained after the single vertical spin ultracentrifugation (Fig. 6),
and contained apo A-I as the only major protein along with 47%
lipid (data not shown). The purified inhibitor, lipid-free apo A-I,
and apo C-Ill showed overlapping dose-response curves which
were linear between 10 and 70% inhibition. Lipase activity was
inhibited by 50% at an inhibitor protein concentration of approx-
imately 30 .rgIml, whereas concentrations above 100 j.tg/ml re-
sulted in virtually complete inhibition. By contrast, the HDL with
apo A-I showed markedly lower inhibition and did not reach a
plateau phase at the concentrations tested. In a separate experi-
ment, the inhibitor activity of native and delipidated HDL (den-
sity 1.063 to 1.21) were compared at different apo A-I concentra-
tions. At an apo A-I concentration of 50 gg/ml, delipidated HDL
showed a 20-fold higher inhibition than native HDL (data not
shown). These experiments clearly demonstrate that the inhibitor
activity associated with apo A-I is modulated by lipids. Further-
more, they suggest that lipase inhibition may be a consequence of
the hydrophobic properties common to all apolipoproteins, since
apo A-I and apo C-Ill exhibited almost identical inhibition per
unit weight in spite of a threefold difference in molecular weight.
Distribution of lipase inhibitor activity in normal and uremic
plasma
The lipasc inhibitor identified as pre-/3-HDL was isolated from
normal plasma only, and in a yield of 4%. Its significance relative
to other putative inhibitors and uremia was therefore unclear. To
explore the role of pre--HDL versus other inhibitors in normal
and uremic subjects, pooled whole plasma and its lipoprotein and
lipoprotein-free fractions were analyzed for apo A-I concentra-
tion and inhibitor activity (Table 2). As expected, the inhibitor
activity in whole uremic plasma (16.6 InhU/ml) was approximately
twice as high as in normal plasma (8.1 InhU!ml). Similarly, the
inhibitor activity of both the lipoprotein and the lipoprotein-free
fractions, reconstituted to the original plasma volume, were twice
as high in the uremic as in the normal samples. Thus, the higher
inhibitor activity in uremic plasma originated from both the
lipoprotein as well as the lipoprotcin-free fractions. It should be
noted, however, that the sum of the fractionated inhibitor activi-
ties from both fractions were almost 50% higher than the inhibitor
activity in whole plasma, suggesting that the fractionation proce-
dure (ultracentrifugation) had released some apo A-I that is
usually bound to HDL particles in whole plasma. Nonetheless, it
appears that apo A-I in uremic plasma is more loosely associated
with the lipoproteins than apo A-I in normal plasma, and more
readily exchanged with the free pool.
In uremic whole plasma and its lipoprotein fraction, the specific
inhibitor activity, normalized to apo A-I concentration, was more
than twice as high as in samples from normal subjects. By contrast,
the specific inhibitor activity of uremic lipoprotein-free plasma
was only 25% higher than normal (Table 2). Although the
concentration of apo A-I was slightly lower in the lipoprotein
fraction and whole plasma from uremic subjects, its concentration
in the lipoprotein-free fraction was almost 70% higher than in
normal subjects. This higher concentration of pre-f3-HDL along
with a higher specific inhibitor activity of both free and lipopro-
tein-associated apo A-I in uremic subjects appears to account for
the greater lipase inhibition by uremic plasma.
To demonstrate differences between uremic and normal sub-
jects in more detail, whole and lipoprotein-free plasma from
either source were also fractionated by anion exchange chroma-
tography on Q-Sepharose, while the effluent was monitored for
protein, apo A-I, and inhibitor activity (Fig. 10). Both normal and
uremic plasma (Fig. 10, upper panel) showed one major peak of
concordant inhibitor activity and apo A-I concentration which
eluted at the same salt concentration as the peak inhibitor activity
during the preparative anion exchange chromatography (Fig. 3).
Although the apo A-I peaks were of similar size in both samples,
the peak inhibitor activity in uremic plasma was more than 50%
higher than in normal plasma. After the main peak, there was
heterogeneous inhibitor activity eluting over a wide range in the
salt gradient. This activity, also appearing to elute concordantly
with apo A-I, was significantly higher in uremic plasma. These
experiments confirm that a major portion of the inhibitor activity
in normal and uremic plasma is associated with apo A-I-contain-
ing particles.
Apo A-I-containing particles emerging as a distinct peak on
preparative anion exchange chromatography (Fig. 3) consisted of
at least two distinct species (Fig. 6) of which the HDL-particles
had a markedly lower specific inhibitor activity than the pre-J3-
HDL in the non-lipoprotcin fraction (Table 1). To determine the
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A B
Fig. 7. SDS-PAGE and immunoblotting of punfied lipase inhibitor from normal plasma. The electrophoresis was performed on a 12% gel under
non-reducing conditions and the gel was either stained with Coomassie (left panel), or electroblotted and immunostained with monospecific goat
anti-human apo A-I IgG followed by alkaline phosphatase-conjugated protein A (right panel). Lanes 1 to 2 contained 0.2 j1 of normal and uremic
plasma, respectively. Lane 3 contained 10 g (left panel) or 1 sg (right panel) of human apo A-I isolated from delipidated HDL. Lane 4 contained 10
sg (left panel) or 1 sg (right panel) of the purified inhibitor obtained after the single vertical spin (Fig. 6).
inhibitory role of pre-f3-HDL without interference from lipopro-
teins, the anion exchange chromatography was also performed
with lipoprotein-free plasma (Fig. 10, lower panel). The apo A-I
peak and especially its concordant inhibitor activity were substan-
tially lower in lipoprotein-free plasma from normal than from
uremic subjects. Both normal and uremic lipoprotein-free plasma
contained additional inhibitor activity in the later part of the salt
gradient that was not associated with measurable apo A-I. Part of
this inhibition may be ascribed to inhibition of LPL activity by a
high salt concentration [26]. These experiments strongly suggest
that the increased inhibitor activity in uremia is primarily associ-
ated with pre-J3-HDL in the non-lipoprotein fraction, although
other inhibitors in the lipoprotein fraction also contribute signif-
icantly.
Discussion
In summary, the present study confirms that plasma from
normal and uremic subjects contains lipase inhibitor activity which
is strongly correlated to plasma triglyceride concentration. Isola-
tion of this activity from normal plasma yielded a particle of 54 A
diameter and pre-/3-electrophoretic mobility which contained apo
A-I as the only major protein along with 3% (wt/wt) phospholipid.
The dose-response curve for its inhibitor activity was practically
identical to that of purified apo A-I and apo C-Ill but substantially
steeper than that of a-migrating HDL containing only apo A-I.
It appears that the isolated inhibitor was a form of pre-13-HDL
("free" apo A-I), a family of lipid-poor particles containing only
apo A-I and found in the non-lipoprotein fraction of plasma
(density > 1.21). Levy and Fredrickson [271 presented immuno-
chemical evidence for an HDL-like particle of slower electro-
phoretic mobility than HDL. Using a combination of immunoaf-
finity chromatography and preparative electrophoresis, Kunitake
et a! [28] isolated a particle with pre-/3-mobility which contained
approximately 90% protein (apo A-I), the remainder being phos-
pholipid and smaller amounts of free and esterified cholesterol. It
had an apparent molecular weight of 80 kDa and a different
protein conformation than a-migrating HDL. Subsequent studies
on the HDL-mediated efflux of cholesterol from cells has shown
that the initial transfer is mediated by pre-/3-migrating apo
A-I-containing particles of various sizes and lipid composition
[29—31]. Pre-/3-HDL can be generated in vitro by incubating HDL
with cholesterol ester transfer protein (CETP) and an acceptor
for cholesterol ester and phospholipid such as LDL or VLDL
[3 1—33]. Conversely, the formation of cholesterol ester mediated
by lecithin:cholestero! acyltransferase (LCAT) stimulates the in-
corporation of apo A-I from pre-f3-HDL into a-migrating HDL
2 1
A
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Fig. 8. Agarose electrophoresis of normal plasma
and punjled inhibitor. A 1% agarose gel was
loaded with 1 1 plasma (60 jtg protein) as a
reference (lane 1) and 2 jig of purified inhibitor
(lane 2) obtained after the single vertical spin
(Fig. 6). The gels were stained for protein (left
panel) and lipid (right panel).
[31, 33]. The particle isolated in the present work had an almost
identical composition but an eightfold larger molecular size
compared to that of pre-13-HDL produced by the incubation of
HDL with CETP and VLDL or LDL [33]. This discrepancy in size
can be ascribed to the concentration-dependent propensity of apo
A-I to self associate into even-numbered oligomers from dimers
to octamers [34]. Because the gel chromatography used to deter-
mine molecular size in the present work employed an enriched
fraction from a large volume of plasma, the apo A-I concentration
was presumably high compared to that used for size determina-
tion in previous work [28, 33]. The isolation procedure described
herein produced pre-f3-HDL and a-migrating HDL containing
only apo A-I, in milligram amounts. It should therefore provide a
useful alternative method to isolate these particles for other
functional and structural studies.
Although LPL and HL are homologous enzymes, LPL requires
apo C-Il as a cofactor for full activity [35], while the need for a
specific activator protein for HL has never been demonstrated
conclusively. However, purified apolipoproteins added to lipase
assays have been shown to inhibit both LPL and HL. Thus LPL
can be inhibited by purified apo A-I [36—38], apo A-lI [36, 37],
apo C-I [36, 39, 40], apo C-Ill [36—42], and apo E [37, 43, 44].
Similarly, inhibition of HL activity has also been demonstrated
with all of the above apoproteins [45—48], as well as with apo C-lI
[47, 48] and HDL [49]. Because two different lipases can be
inhibited by at least five different apolipoproteins, it is conceivable
that the mechanism of inhibition is non-specific and a result of a
common property, most likely the hydrophobic and lipid-binding
character of these apolipoproteins. This notion was confirmed by
the finding that the dose-response curves for lipase inhibition
Apoprotein concentration, ag/mI
Fig. 9. Dose-response curves for inhibition of postheparin plasma lipases.
Purified lipase inhibitor (Fig. 6) was isolated from normal plasma (Table
1). Apo A-I which contained less than 3% (mol/mol) of phospholipid was
isolated from delipidated human HDL. Apo C-Ill was obtained commer-
cially. HDL with apo A-I only was the top fraction from the single vertical
spin (Fig. 6). Apoprotein concentrations of stock inhibitor solutions were
determined by measuring absorbance at 280 nm. The highest concentra-
tions tested were 80 jig/ml for apo C-Ill and 200 jig/mI for the other
proteins. Symbols are: (•) purified inhibitor; (0) ApoA-I; (V) ApoC-Ill;
(0) HDL with ApoA-I.
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Table 2. Comparison of protein, apo A-I concentration, and lipasc
inhibitor activity in whole and fractionated plasma from normal and
uremic subjectsa
Specific
Lipase inhibitor
Protein" ApI AIc inhibitor
activity
activity
Inh U/mg
mg/mi InhU/mi apoA-I
Normal
Whole plasma 49.8 1.76 8.1 4.6
Lipoprotein fraction 3.3 1.57 4.0 2.5
Lipoprotein-free fraction 46.0 0.28 7.6 27.1
Uremic
Whole plasma 51.2 1.59 16.6 10.4
Lipoprotein fraction 4.3 1.21 8.4 6.9
Lipoprotein-free_fraction 46.6 0.47 16.1 34.3
Pooled normal and uremic plasma, obtained by mixing equal volumes
from four subjects each, were separated into a lipoprotein fraction and a
lipoprotein-free fraction by ultracentrifugation at d 1.21 (see Methods).
Before analysis, each fraction was dialyzed against PBS and adjusted to
the original plasma volume (25 ml).
Absorbance at 280 nm
Immunoturbidimetric assay
bythe purified inhibitor, lipid-free apo A-I, and apo C-Ill were
practically identical. Conversely, HDL with apo A-I, in which the
lipid-binding region of the apolipoprotein presumably is occupied,
had substantially less specific inhibitor activity (Fig. 9).
Increased plasma lipase inhibitor activity has been observed in
hypertriglyceridemic conditions such as acute pancreatitis [50],
uremia [12, 141, familial chylomicronemia unrelated to LPL
deficiency [51], and primary hypertriglyceridemia [42]. In all these
studies inhibitor activity was found in the non-lipoprotein frac-
tion. Only in the last study was inhibitor activity also detected in
the lipoprotein fraction [42]. The inhibitor activity associated with
the lipoproteins was correlated with apo C-Ill concentration but
not with other apolipoproteins (apo A-I, A-Il, B, C-Il, D, and E).
The lipase inhibitor in the non-lipoprotein fraction of plasma was
not identified in any of these studies.
Hypertriglyceridemia has also been associated with increased
plasma levels of pre-J3-HDL [52—54]. Because purified apo A-I has
been demonstrated to have lipase inhibitor activity in vitro, it has
also been suggested that pre--HDL may function as a plasma
lipase inhibitor in vivo [55]. In the present work, isolation of the
predominant lipase inhibitor activity from normal plasma yielded
pre-13-HDL (Table 1). Moreover, analytical anion exchange chro-
matography of normal and uremic lipoprotein-free plasma
showed that most of the inhibitor activity eluted concordantly with
apo A-I (Fig. 10, bottom panel). Finally, anti-apo A-I lgG
neutralized the inhibitor activity in lipoprotein-free normal and
uremic plasma almost completely (data not shown). These results
show that most of the inhibitor activity in the non-lipoprotein
fraction of normal and uremic plasma is mediated by pre-/3-HDL.
The elevated plasma concentrations of pre-f3-HDL that are
present in primary hypertriglyceridemia [53, 54] have been sug-
gested to result from increased dissociation of lipid-poor apo A-I
from triglyceride-enriched HDL [56]. Presumably, this should
lead to increased plasma lipase inhibitor activity, the function of
which could be to suppress excessive hydrolysis that would
otherwise result in toxic concentrations of plasma free fatty acid.
Without additional regulatory mechanisms, hypertriglyceridemia
resulting from lipase inhibition would then be a self-sustaining
condition. However, pre-13-HDL is normally eliminated and Ca-
tabolized primarily by the kidney [57, 58]. Furthermore, the ability
of pre-J3-HDL to self-associate (see above) could provide an
additional buffer mechanism protecting against excessive lipase
inhibition.
Chronic renal failure is associated with several lipoprotein
abnormalities as well as altered concentrations of individual
apolipoproteins. The most prominent apolipoprotein changes
pertinent to the present work include an increased plasma con-
centration of apo C-Ill, and a decreased concentration of total
apo A-I [5, 59, 60]. The mechanisms responsible for these changes
are not known [5]. In contrast to total apo A-I, the concentration
of pre-13-HDL ("free" apo A-I) appears to be increased [61, 62].
Since pre-/3-HDL is strongly correlated to plasma creatinine levels
in patients with chronic renal failure, the increased concentration
appears to be a direct result of the renal impairment [61]. This
notion is supported by the finding that catabolism of pre-13-HDL
takes place predominantly in the kidney [57, 58]. In view of the
present work demonstrating a strong correlation between plasma
triglycerides and inhibitor activity in normal and uremic subjects
(Fig. 1), and identifying most of this activity as pre-13-HDL (Table
1), one would anticipate a correlation between pre-3-HDL
("free" apo A-I) and plasma triglycerides. While Schonfeld,
Bailey and Steelman [52] observed a strong correlation between
non-lipoprotein apo A-I and plasma triglycerides in a population
of normal and hyperlipidemic subjects, other investigators were
unable to find such correlations in uremic patients [61, 62]. It
should be noted that pre-p-HDL is a family of apo A-I-containing
particles differing in lipid composition [30]. Conceivably, addi-
tional heterogeneity could be caused by aggregation to oligomers
of different sizes [34]. Assuming that most of the inhibitor activity
of the pre-13-HDL fraction is confined to a small subpopulation of
particles, a strong correlation with plasma triglycerides could be
concealed unless the pertinent species of particles are measured
directly. Finally, attempts to correlate only pre-/3-HDL to triglyc-
eride levels ignore the fact that a significant portion of the
inhibitor activity in uremic plasma resides in the lipoprotein
fraction (Table 3). This enhanced inhibitor activity in the lipopro-
tein fraction could be caused by compositional alterations leading
to increased specific inhibitor activity of apo A-I (Fig. 9) and
possibly other apolipoproteins.
Elevated concentrations of apo C-Ill constitute another major
apolipoprotein alteration in uremia [59, 60, 63]. Apo C-Ill has
also been implicated as an important lipase inhibitor within the
lipoprotein fraction of hypertriglyceridemic plasma [42]. There-
fore, the proposal [60] that accumulation of apo C-Ill causes
uremic hypertriglyceridemia appears to be appropriate. In the
present work, however, there was no indication that apo C-Ill
constituted a significant component in any active fraction moni-
tored by SDS-PAGE during the isolation of inhibitor from plasma
(data not shown). Although it is still plausible that apo C-Ill
contributes to the cause of uremic hypertriglyceridemia, a pre-
dominant role of apo A-I is far more likely because the plasma
concentration of apo A-I is one order of magnitude higher than
that of apo C-Ill [64].
Seres et a! [14] have demonstrated that hemodialysis with high
flux polysulfone membranes resulted in less lipase inhibitor
activity, higher lipase activity, lower triglyceride concentrations,
and higher concentrations of HDL-cho!esterol than dialysis with
0.8
0.6
0.4
Fig. 10. Analytical anion exchange
chromatography of normal and uremic, whole
0 2 and lipoprotein-free plasma, on Q-Sepharose.Pooled normal and uremic plasma were
obtained by mixing equal volumes of plasma
from four subjects each. Lipoprotein-free
0.0 plasma was the bottom fraction obtained after
0.8 ultracentrifugation of 25 ml whole plasma at
density 1.21 (see Methods). Whole plasma (25
ml) or lipoprotein-free plasma from 25 ml of
whole plasma, were dialyzed against 1 m0.6 EDTA-0.05 M Tris-HC1 buffer (pH 8.0), and
diluted to 50 ml with the buffer. The diluted
samples were mixed with 50 ml of sedimented
0 4 Q-Sepharose and stirred for 30 minutes at
room temperature. The suspension was packed
into a column (2.6 x 9.5 cm) equilibrated with
buffer. The column was operated at room
0.2 temperature and a flow rate of 2.5 mI/mm while
2.5 ml fractions were collected. After washing
with 100 ml of buffer, the column was eluted
with a linear gradient (250 ml) from 0 to 0.5 M0.0 NaCl (----) in 1 mrvi EDTA-0.05 M Tris-HC1
buffer (pH 8.0). The fractions were monitored
by measuring absorbance at 280 nm (0), apo
A-I concentration (0), and inhibitor activity(•).
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membranes made of saponified cellulose ester. It appears reason-
able to ascribe these changes in plasma lipids after polysulfone
dialysis to the removal of inhibitors, and consequently, the higher
lipase activity. In contrast, Blankenstijn et a! [65] observed that a
single dialysis session using either high flux polysulfone or low flux
cellulose membranes resulted in similar increases in postheparin
plasma LPL activity and decreases in plasma triglycerides. Despite
the suggestion that polysulfone dialysis removed lipase inhibitors
from the patients' plasma [14], the inhibitors were not identified.
Our results showed that an ultrafiltrate obtained from uremic
plasma using polysulfone membranes did not contain significant
inhibitor activity (Fig. 2), suggesting that these membranes may
remove lipase inhibitor from plasma by adsorption rather than by
dialysis. Although a monomer of pre-f3-I-IDL would be small
enough to traverse the hemodialysis membrane, it is conceivable
that its hydrophobicity would facilitate adsorption of the molecule
onto the membrane, thereby preventing it from appearing in the
ultrafiltrate. Identification of pre-p-HDL as a principal lipase
inhibitor in chronic renal failure should facilitate the development
of new treatment modalities for uremic dyslipidemia.
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Appendix
Abbreviations are: apo, apolipoprotein; BCA, bicinchoninic acid;
CETP, cholesterol ester transfer protein; HDL, high density lipoproteins;
I-IL, hepatic lipase; IDL, intermediate density lipoproteins; InhU, inhibi-
tor unit; KRP, Krebs-Ringer phosphate buffer; LCAT, lecithin:cholesterol
acyltransferase; LPL, lipoprotein lipase; PEG, polyethylene glycol; TCA,
trichioroacetic acid; VLDL, very low density lipoproteins.
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